Display options
Cite
Wąsik A, Białoń M, Jantas D, et al. The Impact of the Combined Administration of 1MeTIQ and MK-801 on Cell Viability, Oxidative Stress Markers, and Glutamate Release in the Rat Hippocampus. Neurotox Res. 2021;39(6):1747-1761doi: 10.1007/s12640-021-00428-9.
Wąsik, A., Białoń, M., Jantas, D., & Żarnowska, M. (2021). The Impact of the Combined Administration of 1MeTIQ and MK-801 on Cell Viability, Oxidative Stress Markers, and Glutamate Release in the Rat Hippocampus. Neurotoxicity research, 39(6), 1747-1761. https://doi.org/10.1007/s12640-021-00428-9
Wąsik, Agnieszka, et al. "The Impact of the Combined Administration of 1MeTIQ and MK-801 on Cell Viability, Oxidative Stress Markers, and Glutamate Release in the Rat Hippocampus." Neurotoxicity research vol. 39,6 (2021): 1747-1761. doi: https://doi.org/10.1007/s12640-021-00428-9
Wąsik A, Białoń M, Jantas D, Żarnowska M. The Impact of the Combined Administration of 1MeTIQ and MK-801 on Cell Viability, Oxidative Stress Markers, and Glutamate Release in the Rat Hippocampus. Neurotox Res. 2021 Dec;39(6):1747-1761. doi: 10.1007/s12640-021-00428-9. Epub 2021 Oct 19. PMID: 34665405; PMCID: PMC8639582.
Copy Download .nbib Format: NLM
Share it on

Neurotox Res. 2021 Dec;39(6):1747-1761. doi: 10.1007/s12640-021-00428-9. Epub 2021 Oct 19.

The Impact of the Combined Administration of 1MeTIQ and MK-801 on Cell Viability, Oxidative Stress Markers, and Glutamate Release in the Rat Hippocampus.

Neurotoxicity research

Agnieszka Wąsik, Magdalena Białoń, Danuta Jantas, Marcelina Żarnowska

Affiliations

  1. Department of Neurochemistry, Maj Institute of Pharmacology PAS, Krakow, Poland. [email protected].
  2. Department of Neurochemistry, Maj Institute of Pharmacology PAS, Krakow, Poland.
  3. Department of Experimental Neuroendocrinology, Maj Institute of Pharmacology PAS, Krakow, Poland.

PMID: 34665405 PMCID: PMC8639582 DOI: 10.1007/s12640-021-00428-9

Abstract

MK-801, as an N-methyl-D-aspartate (NMDA) receptor inhibitor, causes elevation in glutamate release, which may lead to an increase in excitotoxicity, oxidative stress and, consequently, cell death. 1-Methyl-1,2,3,4-tetrahydroisoquinoline (1MeTIQ) shows antioxidant activity. The aim of the present study was to evaluate the effect of combined treatment with 1MeTIQ and MK-801 on cell viability, antioxidant enzyme activity, and glutamate release in the rat hippocampus. Cytotoxicity was measured using lactate dehydrogenase leakage assay (LDH) and the methyl tetrazolium (MTT) assay; antioxidant enzyme activity (glutathione peroxidase (GPx), glutathione reductase (GR), superoxide dismutase (SOD), and catalase (CAT)) were measured by ELISA kits. The release of glutamate in the rat hippocampus was measured using in vivo microdialysis methodology. An in vitro study showed that MK-801 induced cell death in a concentration-dependent manner and that 1MeTIQ partially reduced this adverse effect of MK-801. An ex vivo study indicated that MK-801 produced an increase in antioxidant enzyme activity (GPx, GR, and SOD), whereas coadministration of MK-801 and 1MeTIQ restored the activity of these enzymes to the control level. An in vivo microdialysis study demonstrated that combined treatment with both drugs decreased the release of glutamate in the rat hippocampus. The above results revealed that 1MeTIQ shows limited neuroprotective activity under conditions of glutamate-induced neurotoxicity.

© 2021. The Author(s).

Keywords: 1-Methyl-1,2,3,4-tetrahydroisoquinoline (1MeTIQ); Antioxidant enzymes; Cytotoxicity; Glutamate release; MK-801

References

  1. Neurotox Res. 2014 May;25(4):348-57 - PubMed
  2. Nat Neurosci. 1999 Apr;2(4):311-4 - PubMed
  3. J Neurosci. 1997 Apr 15;17(8):2921-7 - PubMed
  4. Neuroscience. 2009 Jan 12;158(1):293-300 - PubMed
  5. Basic Clin Neurosci. 2013 Winter;4(1):5-23 - PubMed
  6. Neurobiol Learn Mem. 2009 Jul;92(1):89-98 - PubMed
  7. Neurochem Int. 2015 Sep;88:110-23 - PubMed
  8. J Neurol Sci. 2012 Nov 15;322(1-2):254-62 - PubMed
  9. Pharmacol Rep. 2016 Dec;68(6):1205-1213 - PubMed
  10. Curr Opin Pharmacol. 2007 Feb;7(1):48-55 - PubMed
  11. Neuropsychopharmacology. 1989 Dec;2(4):299-308 - PubMed
  12. Life Sci. 2010 Feb 13;86(7-8):260-6 - PubMed
  13. Toxicol In Vitro. 2016 Dec;37:162-168 - PubMed
  14. Mol Psychiatry. 2002;7(1):32-43 - PubMed
  15. Eur J Pharmacol. 2003 Apr 18;466(3):263-9 - PubMed
  16. Neurobiol Learn Mem. 2011 Mar;95(3):221-30 - PubMed
  17. Mol Neurobiol. 2016 May;53(4):2498-509 - PubMed
  18. Dialogues Clin Neurosci. 2000 Sep;2(3):219-32 - PubMed
  19. Front Biosci. 1999 Mar 15;4:D339-45 - PubMed
  20. Mol Cell Endocrinol. 2004 Mar 15;216(1-2):31-9 - PubMed
  21. Pharmacol Rep. 2017 Oct;69(5):851-860 - PubMed
  22. Schizophr Res. 1996 Mar;19(1):1-17 - PubMed
  23. Neurotox Res. 2003;5(6):433-42 - PubMed
  24. Arch Gen Psychiatry. 1995 Dec;52(12):998-1007 - PubMed
  25. Front Neurol. 2018 Apr 13;9:236 - PubMed
  26. Exp Toxicol Pathol. 2003 Mar;54(4):319-34 - PubMed
  27. J Neurosci. 1996 Mar 15;16(6):2034-43 - PubMed
  28. BMC Psychiatry. 2020 Mar 6;20(1):106 - PubMed
  29. Int J Neuropsychopharmacol. 2004 Jun;7(2):155-63 - PubMed
  30. Mol Psychiatry. 1999 Jul;4(4):344-52 - PubMed
  31. Pharmacol Biochem Behav. 2016 Apr;143:18-25 - PubMed
  32. Prog Neuropsychopharmacol Biol Psychiatry. 2007 May 9;31(4):832-8 - PubMed
  33. Neurosci Lett. 2006 May 8;398(3):241-5 - PubMed
  34. Nat Neurosci. 2011 Feb;14(2):147-53 - PubMed
  35. Int Rev Psychiatry. 2006 Apr;18(2):119-31 - PubMed
  36. Life Sci. 2011 Jun 20;88(25-26):1136-41 - PubMed
  37. Schizophr Res. 2013 Jun;147(1):14-23 - PubMed
  38. J Psychopharmacol. 2007 Jun;21(4):440-52 - PubMed
  39. Toxicology. 2000 Nov 16;153(1-3):83-104 - PubMed
  40. J Neurochem. 2006 May;97(3):846-56 - PubMed
  41. FASEB J. 1995 May;9(8):605-10 - PubMed
  42. Brain Res. 1992 Aug 7;587(2):233-40 - PubMed
  43. Behav Brain Res. 2012 May 16;231(1):1-10 - PubMed
  44. Neurotox Res. 2016 Apr;29(3):351-63 - PubMed
  45. Pol J Pharmacol. 2004 Nov-Dec;56(6):727-34 - PubMed
  46. J Neurosci Methods. 1987 May;20(1):83-90 - PubMed
  47. World Psychiatry. 2020 Feb;19(1):15-33 - PubMed
  48. Acta Biochim Biophys Sin (Shanghai). 2016 Mar;48(3):209-19 - PubMed
  49. Neurotox Res. 2014 Jan;25(1):1-12 - PubMed
  50. Methods Cell Biol. 1998;57:251-64 - PubMed
  51. Biochemistry. 1963 Nov-Dec;2:1420-8 - PubMed
  52. Neurotox Res. 2009 Nov;16(4):390-407 - PubMed
  53. Synapse. 1987;1(2):133-52 - PubMed
  54. Brain. 2001 May;124(Pt 5):849-81 - PubMed
  55. J Neural Transm (Vienna). 2002 Sep;109(9):1159-80 - PubMed
  56. Neuropharmacology. 2018 Oct;141:223-237 - PubMed
  57. Toxicol Lett. 2006 Jan 5;160(2):171-7 - PubMed
  58. Prog Neuropsychopharmacol Biol Psychiatry. 2002 Jun;26(5):995-1005 - PubMed
  59. Mol Psychiatry. 2019 May;24(5):633-642 - PubMed
  60. J Neurosci. 1998 Jul 15;18(14):5545-54 - PubMed
  61. J Neurosci. 2017 Nov 8;37(45):10800-10807 - PubMed
  62. J Neurochem. 2000 Jul;75(1):65-71 - PubMed
  63. Free Radic Biol Med. 2003 Jan 15;34(2):145-69 - PubMed
  64. J Neurochem. 1992 May;58(5):1760-7 - PubMed
  65. J Neurosci Res. 1996 Oct 01;46(1):82-9 - PubMed
  66. Neurotoxicology. 2007 Jan;28(1):161-7 - PubMed

Publication Types

Grant support